CY2016010I2 - Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια - Google Patents

Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια

Info

Publication number
CY2016010I2
CY2016010I2 CY2016010C CY2016010C CY2016010I2 CY 2016010 I2 CY2016010 I2 CY 2016010I2 CY 2016010 C CY2016010 C CY 2016010C CY 2016010 C CY2016010 C CY 2016010C CY 2016010 I2 CY2016010 I2 CY 2016010I2
Authority
CY
Cyprus
Prior art keywords
polypeptides
compositions
Prior art date
Application number
CY2016010C
Other languages
English (en)
Other versions
CY2016010I1 (el
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of CY2016010I1 publication Critical patent/CY2016010I1/el
Publication of CY2016010I2 publication Critical patent/CY2016010I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
CY2016010C 2003-11-28 2016-05-05 Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια CY2016010I2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03027511 2003-11-28
EP04803302A EP1691833B1 (en) 2003-11-28 2004-11-26 Compositions comprising polypeptides
PCT/EP2004/013445 WO2005052004A2 (en) 2003-11-28 2004-11-26 Compositions comprising polypeptides

Publications (2)

Publication Number Publication Date
CY2016010I1 CY2016010I1 (el) 2016-08-31
CY2016010I2 true CY2016010I2 (el) 2016-08-31

Family

ID=34626385

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100465T CY1110689T1 (el) 2003-11-28 2010-05-27 Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
CY2016010C CY2016010I2 (el) 2003-11-28 2016-05-05 Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20101100465T CY1110689T1 (el) 2003-11-28 2010-05-27 Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια

Country Status (17)

Country Link
US (1) US10000574B2 (el)
EP (2) EP2186527A1 (el)
AT (1) ATE459374T1 (el)
AU (1) AU2004293182B2 (el)
BE (1) BE2016C023I2 (el)
CA (1) CA2544532C (el)
CY (2) CY1110689T1 (el)
DE (1) DE602004025840D1 (el)
DK (1) DK1691833T3 (el)
ES (1) ES2341252T3 (el)
HU (1) HUS1600019I1 (el)
LU (1) LU93067I2 (el)
NL (1) NL300807I2 (el)
PL (1) PL1691833T3 (el)
PT (1) PT1691833E (el)
SI (1) SI1691833T1 (el)
WO (1) WO2005052004A2 (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
US9308257B2 (en) * 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
PT2632954E (pt) 2010-10-27 2016-02-03 Amgen Res Munich Gmbh Meios e métodos para tratar dlbcl
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
JP2017507900A (ja) 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
JP2017501157A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
KR102355609B1 (ko) 2014-05-29 2022-01-27 마크로제닉스, 인크. 다중 암 항원에 특이적으로 결합하는 삼중-특이적 결합 분자 및 그것의 사용 방법
US10066002B2 (en) 2014-11-05 2018-09-04 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016073791A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
JP2018508481A (ja) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
AU2016280070B2 (en) 2015-06-17 2022-09-15 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN108289952B (zh) 2015-11-19 2021-02-05 雷维托普有限公司 用于对非所要细胞进行重定向杀灭的两组分***的功能性抗体片段互补作用
BR112018003984A2 (pt) 2015-12-09 2018-09-25 Hoffmann La Roche anticorpos
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CA3059010A1 (en) 2016-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
EP3497129A1 (en) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
PL3559034T3 (pl) 2016-12-20 2021-04-19 F. Hoffmann-La Roche Ag Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
CN111315781A (zh) 2017-11-01 2020-06-19 豪夫迈·罗氏有限公司 用靶向性ox40激动剂的组合疗法
WO2019175071A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
EP3765501A1 (en) 2018-03-13 2021-01-20 F. Hoffmann-La Roche AG Combination therapy with targeted 4-1bb (cd137) agonists
JP7383704B2 (ja) * 2018-06-07 2023-11-20 カリナン オンコロジー インコーポレイテッド 多重特異性結合タンパク質およびその使用方法
EP4249917A3 (en) 2018-09-21 2023-11-08 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
TW202031899A (zh) 2018-11-05 2020-09-01 美商建南德克公司 在原核宿主細胞中產生二鏈蛋白質之方法
EP3962948A1 (en) 2019-04-30 2022-03-09 Amgen Research (Munich) GmbH Means and methods of treating burkitt lymphoma or leukemia
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
KR102453073B1 (ko) * 2020-08-14 2022-10-11 건국대학교 글로컬산학협력단 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
JP2024516631A (ja) 2021-04-23 2024-04-16 プロファウンドバイオ ユーエス カンパニー 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
IL307821A (en) 2021-04-30 2023-12-01 Hoffmann La Roche Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
EP4083061A1 (en) * 2021-04-30 2022-11-02 Kilometro Rosso SPA Fusion proteins and use thereof in the treatment of membranous nephropathy
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP2024517042A (ja) 2022-04-13 2024-04-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の薬学的組成物及び使用方法
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH06508985A (ja) 1991-02-27 1994-10-13 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 富セリンペプチドリンカー
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
JP4169478B2 (ja) * 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
AU2002363339B2 (en) * 2001-11-08 2008-02-07 Abbvie Biotechnology Ltd Stable liquid pharmaceutical formulation of IGG antibodies

Also Published As

Publication number Publication date
US20070249529A1 (en) 2007-10-25
HUS1600019I1 (hu) 2016-06-28
US10000574B2 (en) 2018-06-19
AU2004293182B2 (en) 2010-02-18
PT1691833E (pt) 2010-06-08
CA2544532C (en) 2015-06-16
EP2186527A1 (en) 2010-05-19
BE2016C023I2 (el) 2023-12-18
AU2004293182A1 (en) 2005-06-09
CY2016010I1 (el) 2016-08-31
CA2544532A1 (en) 2005-06-09
DE602004025840D1 (de) 2010-04-15
ATE459374T1 (de) 2010-03-15
EP1691833B1 (en) 2010-03-03
EP1691833A2 (en) 2006-08-23
CY1110689T1 (el) 2015-06-10
NL300807I2 (el) 2016-10-13
PL1691833T3 (pl) 2010-08-31
LU93067I2 (fr) 2016-07-11
WO2005052004A2 (en) 2005-06-09
ES2341252T3 (es) 2010-06-17
SI1691833T1 (sl) 2010-06-30
DK1691833T3 (da) 2010-05-03
WO2005052004A3 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
CY2016010I1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
DE602004020635D1 (de) Lanzetten betreffende verbesserungen
FR2862654B1 (fr) Composition amylacee filmogene
DE50310628D1 (de) Erfahren
DE602004004264D1 (de) Schalter
DE10393374D2 (de) Zusammensetzung
SE0500163L (sv) Sammansättning
DK1561472T3 (da) Faststofsammensætning
DE112004001733A5 (de) Schalter
DE60320902D1 (de) Zusammensetzungen mit ausgelöster Freisetzung
DE502004008876D1 (de) En schaltglied
DE602004004388D1 (de) Verdickbare zusammensetzungen
DE602004021338D1 (de) Gasflüssigkeitsabscheider
DE602004024235D1 (de) Amidoacetonitrilderivate
DK1664095T3 (da) Antimikrobielle polypeptider
BR0310113B1 (pt) Composições pesticidas
DK1633719T3 (da) Substituerede spirobenzazepiner
DK1625148T3 (da) Peptidkompleks
DE50309081D1 (de) Neue diketopyrrolopyrrolpigmente
ATE365529T1 (de) Schweisshemmende zusammensetzungen
NO20044140D0 (no) New Composition
DE502004007959D1 (de) Prolinylarylacetamide
NO20053512D0 (no) IL-8-liknende proteiner
FR2861257B1 (fr) Composition herbicide
NO20050436D0 (no) Beta-lagnedbrytende peptider